CanSino Moving Coronavirus Vaccine To Phase III
CanSino plans to start a Phase III study soon for its candidate with a 40,000 enrollment target, discloses its co-founder.
You may also be interested in...
Deal brings in new funding and commercial partner for CureVac, and gives GSK greater stake in fast-developing mRNA field.
Coronavirus Update: 'We Are Racing Against The Virus, Not America,' Says China’s Vaccine Frontrunner
Plus new biotech company Adagio Therapeutics has been launched with a $50m series A financing to advance its coronavirus antibodies as therapeutics and prophylactics.
FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.